{
  "data": {
    "id": "org_phrma",
    "slug": "phrma",
    "name": "PhRMA",
    "short_name": "PhRMA",
    "type": "association",
    "tier": 2,
    "homepage": "https://phrma.org",
    "country_code": "US",
    "reliability_note": null,
    "url": "https://statorigin.org/sources/phrma",
    "documents": [
      {
        "title": "Research & Development",
        "url": "https://phrma.org/policy-issues/research-development",
        "doc_type": "press_release",
        "published_date": null,
        "accessed_at": "2026-09-17",
        "license": "see-source",
        "url_status": "ok",
        "statistic_count": 7
      }
    ],
    "statistics": [
      {
        "id": "stat_MBM4FPC6Q63D53V4H7947N7R0N",
        "url": "https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N",
        "indicator": {
          "slug": "approved-immunotherapy-drugs-multi-year-total",
          "name": "Approved immunotherapy drugs (multi-year total)",
          "definition": "Cumulative number of immunotherapy pharmaceutical products authorized for therapeutic use."
        },
        "industry": [
          {
            "slug": "pharmaceuticals",
            "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
            "isic": "C21",
            "is_primary": true
          }
        ],
        "region": {
          "code": "US",
          "name": "United States",
          "type": "country"
        },
        "period": {
          "start": "2010-01-01",
          "end": "2025-12-31",
          "type": "year"
        },
        "value": 30,
        "value_text": "over 30",
        "unit": "count",
        "currency": null,
        "scale": "1",
        "value_type": "actual",
        "source": {
          "org": "PhRMA",
          "org_short_name": "PhRMA",
          "org_url": "https://phrma.org",
          "org_tier": 2,
          "document_title": "Research & Development",
          "document_url": "https://phrma.org/policy-issues/research-development",
          "document_type": "press_release",
          "locator": "Revolutionizing Cancer Care with Immunotherapy",
          "quote": "Since 2010, over 30 immunotherapy drugs have been approved to treat 25 types of cancer.",
          "published_date": null,
          "accessed_at": "2026-09-17",
          "license": "see-source",
          "url_status": "ok"
        },
        "verification": "verified",
        "verified_by": "seed:auto-extract-v1",
        "verified_at": "2026-09-17T07:16:01.811Z",
        "confidence": 0.9,
        "is_secondhand": false,
        "supersedes": null,
        "superseded_by": null,
        "is_current": true,
        "citation": {
          "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N",
          "bibtex": "@misc{phrma2025approved7n7r0n,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
        },
        "updated_at": "2026-09-17T07:16:01.811Z"
      },
      {
        "id": "stat_FRE7CHVKGNJN3911RBNGBJF45S",
        "url": "https://statorigin.org/stat/stat_FRE7CHVKGNJN3911RBNGBJF45S",
        "indicator": {
          "slug": "average-cost-to-develop-a-new-medicine",
          "name": "Average cost to develop a new medicine",
          "definition": "Estimated average capitalized expenditure required to discover, clinically test, and license a new pharmaceutical product."
        },
        "industry": [
          {
            "slug": "pharmaceuticals",
            "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
            "isic": "C21",
            "is_primary": true
          }
        ],
        "region": {
          "code": "GLOBAL",
          "name": "Global",
          "type": "world"
        },
        "period": {
          "start": "2025-01-01",
          "end": "2025-12-31",
          "type": "point"
        },
        "value": 2.6,
        "value_text": "$2.6 billion",
        "unit": "USD",
        "currency": "USD",
        "scale": "billion",
        "value_type": "estimate",
        "source": {
          "org": "PhRMA",
          "org_short_name": "PhRMA",
          "org_url": "https://phrma.org",
          "org_tier": 2,
          "document_title": "Research & Development",
          "document_url": "https://phrma.org/policy-issues/research-development",
          "document_type": "press_release",
          "locator": "Progress toward New Medicines and Vaccines",
          "quote": "On average, it takes 10-15 years and costs $2.6 billion to develop one new medicine, including the cost of the many failures.",
          "published_date": null,
          "accessed_at": "2026-09-17",
          "license": "see-source",
          "url_status": "ok"
        },
        "verification": "verified",
        "verified_by": "seed:auto-extract-v1",
        "verified_at": "2026-09-17T07:16:01.811Z",
        "confidence": 0.9,
        "is_secondhand": false,
        "supersedes": null,
        "superseded_by": null,
        "is_current": true,
        "citation": {
          "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_FRE7CHVKGNJN3911RBNGBJF45S",
          "bibtex": "@misc{phrma2025averagebjf45s,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_FRE7CHVKGNJN3911RBNGBJF45S},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
        },
        "updated_at": "2026-09-17T07:16:01.811Z"
      },
      {
        "id": "stat_AA927K4APEG4WA76H7YWADD4EW",
        "url": "https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW",
        "indicator": {
          "slug": "biopharmaceutical-r-d-expenditure-multi-year-total",
          "name": "Biopharmaceutical R&D expenditure (multi-year total)",
          "definition": "Total capital expenditure invested by biopharmaceutical companies into research and development of new medicines."
        },
        "industry": [
          {
            "slug": "pharmaceuticals",
            "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
            "isic": "C21",
            "is_primary": true
          }
        ],
        "region": {
          "code": "US",
          "name": "United States",
          "type": "country"
        },
        "period": {
          "start": "2015-01-01",
          "end": "2024-12-31",
          "type": "year"
        },
        "value": 900,
        "value_text": "over $900 billion",
        "unit": "USD",
        "currency": "USD",
        "scale": "billion",
        "value_type": "actual",
        "source": {
          "org": "PhRMA",
          "org_short_name": "PhRMA",
          "org_url": "https://phrma.org",
          "org_tier": 2,
          "document_title": "Research & Development",
          "document_url": "https://phrma.org/policy-issues/research-development",
          "document_type": "press_release",
          "locator": "Policy Framework",
          "quote": "Over the past decade, PhRMA member companies have invested over $900 billion in developing new treatments and cures, yielding groundbreaking results.",
          "published_date": null,
          "accessed_at": "2026-09-17",
          "license": "see-source",
          "url_status": "ok"
        },
        "verification": "verified",
        "verified_by": "seed:auto-extract-v1",
        "verified_at": "2026-09-17T07:16:01.811Z",
        "confidence": 0.9,
        "is_secondhand": false,
        "supersedes": null,
        "superseded_by": null,
        "is_current": true,
        "citation": {
          "apa": "PhRMA. (2024). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW",
          "bibtex": "@misc{phrma2024biopharmaceuticaladd4ew,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2024},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
        },
        "updated_at": "2026-09-17T07:16:01.811Z"
      },
      {
        "id": "stat_V2J1XACMRQE968NSWN5E8TT1Q5",
        "url": "https://statorigin.org/stat/stat_V2J1XACMRQE968NSWN5E8TT1Q5",
        "indicator": {
          "slug": "clinical-development-regulatory-approval-rate",
          "name": "Clinical development regulatory approval rate",
          "definition": "Proportion of drug candidates entering clinical trials that successfully receive regulatory marketing authorization."
        },
        "industry": [
          {
            "slug": "pharmaceuticals",
            "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
            "isic": "C21",
            "is_primary": true
          }
        ],
        "region": {
          "code": "US",
          "name": "United States",
          "type": "country"
        },
        "period": {
          "start": "2025-01-01",
          "end": "2025-12-31",
          "type": "point"
        },
        "value": 12,
        "value_text": "12%",
        "unit": "percent",
        "currency": null,
        "scale": "1",
        "value_type": "estimate",
        "source": {
          "org": "PhRMA",
          "org_short_name": "PhRMA",
          "org_url": "https://phrma.org",
          "org_tier": 2,
          "document_title": "Research & Development",
          "document_url": "https://phrma.org/policy-issues/research-development",
          "document_type": "press_release",
          "locator": "Progress toward New Medicines and Vaccines",
          "quote": "Only 12% of new molecular entities that enter clinical trials eventually receive U.S. Food and Drug Administration (FDA) approval.",
          "published_date": null,
          "accessed_at": "2026-09-17",
          "license": "see-source",
          "url_status": "ok"
        },
        "verification": "verified",
        "verified_by": "seed:auto-extract-v1",
        "verified_at": "2026-09-17T07:16:01.811Z",
        "confidence": 0.9,
        "is_secondhand": false,
        "supersedes": null,
        "superseded_by": null,
        "is_current": true,
        "citation": {
          "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_V2J1XACMRQE968NSWN5E8TT1Q5",
          "bibtex": "@misc{phrma2025clinical8tt1q5,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_V2J1XACMRQE968NSWN5E8TT1Q5},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
        },
        "updated_at": "2026-09-17T07:16:01.811Z"
      },
      {
        "id": "stat_C9H3H7G4QK2418S8SH3H1NE64T",
        "url": "https://statorigin.org/stat/stat_C9H3H7G4QK2418S8SH3H1NE64T",
        "indicator": {
          "slug": "cumulative-biopharmaceutical-r-d-expenditure",
          "name": "Cumulative biopharmaceutical R&D expenditure",
          "definition": "Cumulative capital expenditure invested in biopharmaceutical research and development across member companies over a designated period."
        },
        "industry": [
          {
            "slug": "pharmaceuticals",
            "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
            "isic": "C21",
            "is_primary": true
          }
        ],
        "region": {
          "code": "US",
          "name": "United States",
          "type": "country"
        },
        "period": {
          "start": "2000-01-01",
          "end": "2025-12-31",
          "type": "year"
        },
        "value": 1,
        "value_text": "over $1 trillion dollars",
        "unit": "USD",
        "currency": "USD",
        "scale": "trillion",
        "value_type": "actual",
        "source": {
          "org": "PhRMA",
          "org_short_name": "PhRMA",
          "org_url": "https://phrma.org",
          "org_tier": 2,
          "document_title": "Research & Development",
          "document_url": "https://phrma.org/policy-issues/research-development",
          "document_type": "press_release",
          "locator": "Committed to Research",
          "quote": "PhRMA member companies have invested over $1 trillion dollars in R&D since 2000, establishing the biopharmaceutical sector as the most R&D-intensive industry in the U.S. economy.",
          "published_date": null,
          "accessed_at": "2026-09-17",
          "license": "see-source",
          "url_status": "ok"
        },
        "verification": "verified",
        "verified_by": "seed:auto-extract-v1",
        "verified_at": "2026-09-17T07:16:01.811Z",
        "confidence": 0.9,
        "is_secondhand": false,
        "supersedes": null,
        "superseded_by": null,
        "is_current": true,
        "citation": {
          "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_C9H3H7G4QK2418S8SH3H1NE64T",
          "bibtex": "@misc{phrma2025cumulative1ne64t,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_C9H3H7G4QK2418S8SH3H1NE64T},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
        },
        "updated_at": "2026-09-17T07:16:01.811Z"
      },
      {
        "id": "stat_XSG6P8V0F3VTB587F52D5YQZNK",
        "url": "https://statorigin.org/stat/stat_XSG6P8V0F3VTB587F52D5YQZNK",
        "indicator": {
          "slug": "medicines-in-clinical-development",
          "name": "Medicines in clinical development",
          "definition": "Total number of medicines actively undergoing clinical development."
        },
        "industry": [
          {
            "slug": "pharmaceuticals",
            "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
            "isic": "C21",
            "is_primary": true
          }
        ],
        "region": {
          "code": "GLOBAL",
          "name": "Global",
          "type": "world"
        },
        "period": {
          "start": "2025-01-01",
          "end": "2025-12-31",
          "type": "year"
        },
        "value": 8000,
        "value_text": "more than 8,000",
        "unit": "count",
        "currency": null,
        "scale": "1",
        "value_type": "estimate",
        "source": {
          "org": "PhRMA",
          "org_short_name": "PhRMA",
          "org_url": "https://phrma.org",
          "org_tier": 2,
          "document_title": "Research & Development",
          "document_url": "https://phrma.org/policy-issues/research-development",
          "document_type": "press_release",
          "locator": "Policy Framework",
          "quote": "With more than 8,000 medicines in clinical development, the future of medicine is brighter than ever.",
          "published_date": null,
          "accessed_at": "2026-09-17",
          "license": "see-source",
          "url_status": "ok"
        },
        "verification": "verified",
        "verified_by": "seed:auto-extract-v1",
        "verified_at": "2026-09-17T07:16:01.811Z",
        "confidence": 0.9,
        "is_secondhand": false,
        "supersedes": null,
        "superseded_by": null,
        "is_current": true,
        "citation": {
          "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_XSG6P8V0F3VTB587F52D5YQZNK",
          "bibtex": "@misc{phrma2025medicines5yqznk,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_XSG6P8V0F3VTB587F52D5YQZNK},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
        },
        "updated_at": "2026-09-17T07:16:01.811Z"
      },
      {
        "id": "stat_3G0PECR75YC670M97PDAEJET36",
        "url": "https://statorigin.org/stat/stat_3G0PECR75YC670M97PDAEJET36",
        "indicator": {
          "slug": "rare-diseases-treatment-availability-rate",
          "name": "Rare diseases treatment availability rate",
          "definition": "Percentage of recognized rare diseases for which at least one approved therapeutic treatment exists."
        },
        "industry": [
          {
            "slug": "pharmaceuticals",
            "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
            "isic": "C21",
            "is_primary": true
          }
        ],
        "region": {
          "code": "GLOBAL",
          "name": "Global",
          "type": "world"
        },
        "period": {
          "start": "2025-01-01",
          "end": "2025-12-31",
          "type": "point"
        },
        "value": 5,
        "value_text": "5%",
        "unit": "percent",
        "currency": null,
        "scale": "1",
        "value_type": "estimate",
        "source": {
          "org": "PhRMA",
          "org_short_name": "PhRMA",
          "org_url": "https://phrma.org",
          "org_tier": 2,
          "document_title": "Research & Development",
          "document_url": "https://phrma.org/policy-issues/research-development",
          "document_type": "press_release",
          "locator": "Progress toward New Medicines and Vaccines",
          "quote": "Approximately 7,000 rare diseases exist today yet only 5% have an available treatment.",
          "published_date": null,
          "accessed_at": "2026-09-17",
          "license": "see-source",
          "url_status": "ok"
        },
        "verification": "verified",
        "verified_by": "seed:auto-extract-v1",
        "verified_at": "2026-09-17T07:16:01.811Z",
        "confidence": 0.9,
        "is_secondhand": false,
        "supersedes": null,
        "superseded_by": null,
        "is_current": true,
        "citation": {
          "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_3G0PECR75YC670M97PDAEJET36",
          "bibtex": "@misc{phrma2025rareejet36,\n  author       = {{PhRMA}},\n  title        = {Research \\& Development},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_3G0PECR75YC670M97PDAEJET36},\n  note         = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}"
        },
        "updated_at": "2026-09-17T07:16:01.811Z"
      }
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 7,
    "note": "Statistics are capped at 100 per request. Use /statistics?source_org=phrma with a cursor to page through everything."
  }
}